ABCB1 p.Gly449Ala
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 17159598
[PubMed]
Deeken JF et al: "Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics."
No.
Sentence
Comment
178
Table 5 Ethnic frequency (%) of allelic variants in CYP2C9 Allelic variant SNPs Caucasians African-Americans Asians Hispanics Africans CYP2C9*2 C430T 6.8-13.2 1.0-2.5 0 8.0 CYP2C9*3 A1075C 4.3-15.9 0.5-1.25 0-2.2 6.0 CYP2C9*5 C1080G 0 1.7 CYP2C9*7 C55A 7.1 CYP2C9*8 G449A 6.7 7.1 CYP2C9*9 A752G 0.5 13.3 14.3 CYP2C9*11 C1003T 1 CYP2C9*12 C1465T 0.5 SNP, single nucleotide polymorphism. Sources: Caucasians [51-54], African Americans [52,54,55], Asians [52,56], Hispanics [57], Africans [52].
X
ABCB1 p.Gly449Ala 17159598:178:266
status: NEW
PMID: 26014942
[PubMed]
Chaorattanakawee S et al: "Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance."
No.
Sentence
Comment
136
C580Y was most prevalent and was found in 66%, whereas R539T accounted for 15% and Y493H, N458Y, and G449A occurred at lower frequencies of 2.5%, 1.0%, and 0.2%, respectively.
X
ABCB1 p.Gly449Ala 26014942:136:101
status: NEW